News

If you have CLL or SLL, let us know your experience of treatment and your views on potential future treatments by taking part in an online survey.

How can I find out about a trial that may be suitable for me?

This year, the British Society for Haematology held their annual scientific meeting online. Clinical experts presented some of the latest developments across all areas of lymphoma research.

Centres in Southampton, Oxford, Portsmouth, Nottingham, Leicester, Norfolk and Newcastle are inviting people with lymphoma to take part in a research study. 

Research participants needed for study of lung cancer screening decision-making after Hodgkin lymphoma. 

Results of the ZUMA-5 trial show that CAR T-cell therapy has high response rates in relapsed or refractory follicular lymphoma or marginal zone lymphoma.

Study of treatment decisions in Hodgkin lymphoma.

MATRix-RICE chemotherapy followed by a stem cell transplant shows favourable outcomes in people with lymphoma that has spread to the brain or spinal cord.

Lymphoma Action ensure that the patient voice is heard at HTAs, resulting in better access to the latest treatments.

Tafasitamab plus lenalidomide show promise for people with relapsed or refractory DLBCL who are not suitable for a stem cell transplant.

Selinexor shows early potential for people with relapsed or refractory DLBCL who have had at least two previous courses of treatment.

The American Society of Clinical Oncology (ASCO) held a virtual conference at the end of May.

Acalabrutinib shows potential as a chemotherapy-free treatment option for people with CLL who have not been treated before.

Clinical trial results published.

A new blood test has been developed that could be used to screen for more than 50 types of cancer, including lymphoma.

Results of the LEGEND trial of a lenalidomide-based regimen in DLBCL have been published in the Annals of Haematology.

The FLYER study found that four cycles of R-CHOP was no less effective than six cycles in people with stage 1 or 2 high-grade B-cell lymphoma and no risk factors.

Phase 2 trial finds that acalabrutinib is active and well tolerated in people with Waldenström’s macroglobulinaemia

Promising results published in the Journal of Clinical Oncology in November. 

We want to hear from you! Please share your experiences in this new survey.

Promising early results of the KEYNOTE-51 study published in the Lancet Oncology

A recent study published by Macmillan Cancer Support has found that most people who have chronic cancer are not getting the support they need.

Over 3,000 people have entered the HORIZONS study into the impact of cancer diagnosis and treatment on everyday life, including 719 people with lymphoma.

A new ‘gene signature’ might help predict who will respond well to traditional chemotherapy and who might need alternative treatment.

A protein called sIL-2R might help predict outcomes in people with classical Hodgkin lymphoma.

Women diagnosed with Hodgkin lymphoma during pregnancy can be successfully treated during pregnancy with no harm to the unborn child.

Focus on... T-cell lymphomas

Share your experiences in a focus group in Manchester or London.

Our clinical trials information service turns 3 this week - and what a busy 3 years it has been!

Phase 3 study reports better outcomes.

Results of a phase 3 trial for people with CLL with other medical conditions

AstraZeneca announced interim results from their phase 3 ASCEND trial at the European Hematology Association Congress #EHA24 last month

The Lancet Oncology has recently published results of a phase 1 trial of a potential new treatment for T-cell skin lymphoma

Here we summarise some of the latest lymphoma research presented at the American Society of Clinical Oncology's annual meeting in Chicago in June.

Phase 2 study finds that a new treatment combination may improve outcomes for people with relapsed or refractory Hodgkin lymphoma.

Recognising the importance of clinical trials and thanking all those involved

Two recent studies have looked at whether the particular molecular subtype of DLBCL can be used to tailor a person's treatment.

A recent clinical trial found that giving two additional doses of rituximab to people with aggressive B-cell lymphoma who responded to six cycles of R-CHOP did not improve outcomes.

Adding polatuzumab vedotin to bendamustine and rituximab improves survival in patients with relapsed or refractory DLBCL.

Study shows people want better preparation for transition from treatment to follow-up.

Duvelisib reports promising efficacy in people with low-grade non-Hodgkin lymphomas who have not responded to previous treatment.

Teenage and Young Adult Cancer Study published.

Share your views on access to the latest cancer drugs.

UK study researching impact of cancer on daily life across the UK.

Results of the Echelon-2 study show that adding brentuximab vedotin to chemotherapy improves survival in people who have CD30-positive T-cell lymphomas

The National Cohort Study researching late effects of Hodgkin lymphoma treatment will be the largest study of its kind in the world

A negative PET scan after two cycles of eBEACOPP allows treatment intensity to be reduced without affecting disease control

New trial shows a combination of ibrutinib and obinutuzumab is an alternative to ibrutinib plus chemo in first-line treatment of CLL/SLL

Top 10 research priorities to help people live better with and beyond cancer.

People recently diagnosed with mycosis fungoides and Sézary syndrome may be able to join study

Initial clinical trial results shows this could be a potential treatment.

Scientists whose work underpins a targeted treatment for lymphoma win Nobel Prize for Medicine.

The RATHL Trial and the need to establish the impact of different chemotherapies on fertility.

Education and Training Manager Helen Mee reflects on the first of a series of conferences for people with lymphoma

Your insight could support a NICE assessment for brentuximab vedotin

Dr Becky Salisbury, our Senior Medical Writer, blogs about one of the hot topics from the recent British Society of Haematology meeting. 

If you have used Lymphoma TrialsLink, your feedback could help us improve this information service

If you would like to share your views on how cancer care could be improved, Cancer52 would like to hear from you.  

Our Education and Training Manager, Helen Mee, talks about our upcoming event in Glasgow and explains why you should join us

Should obinutuzumab be used as part of the first-line treatment of follicular lymphoma or should we stick with rituximab?

Our Senior Medical Writer, Dr Becky Salisbury, talks about some of the hot topics raised at the recent British Society of Haematology meeting. 

Our Senior Medical Writer, Dr Becky Salisbury, talks about some of the hot topics raised at the recent British Society of Haematology meeting. 

Promising results for new antibody treatment for B-cell lymphomas in ongoing Hu5F9-G4 clinical trial

Lymphoma Canada is seeking the views of peripheral T-cell lymphoma patients who have experience of pralatrexate or belinostat.

Share your experiences in new study from Opinion Health, a UK healthcare research firm. 

Lymphoma Canada is seeking the views of DLBCL patients who have had CAR-T Cell therapy. 

Becky, our senior medical writer, looks at new approaches for high-grade non-Hodgkin lymphoma, discussed at the ASH meeting in December. 

Becky, our senior medical writer, looks at some of the questions raised about maintenance for follicular lymphoma at the post-ASH meeting. 

Becky, our senior medical writer, provides the latest instalment from the 2017 meeting of the American Society of Hematology. 

Becky, our senior medical writer, provides the latest update from the 2017 meeting of the American Society of Hematology. 

Initial results from the phase 1/2 LYMRIT-37-01 clinical trial testing betalutin.

Becky, our senior medical writer, provides part one of an update from the 2017 meeting of the American Society of Hematology. 

Initial results from the phase 2 SADAL trial, which has re-opened.

Results from the phase 2 CLARITY clinical trial have informed new treatment groups in the ongoing FLAIR trial.

Encouraging results from the first part of the ongoing OASIS clinical trial.

Early results from the phase 1/2 trial of G100 are encouraging.

People with certain mutations (genetic changes) in their lymphoma cells are most likely to benefit.

MOR2018 and lenalidomide could be a new treatment combination for diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond well) to previous treatment.

New approaches are needed for the treatment of people with T-cell lymphoma after disappointing results in the CHEMO-T trial.

Adding rituximab to chemotherapy improves outcomes for under-18s with advanced-stage B-cell non-Hodgkin lymphoma (NHL)

Recently published findings from the phase 3 RATHL trial (Response-adapted therapy for advanced Hodgkin lymphoma) show that most people can be spared some side effects.